Drug evaluation: ISIS-301012, an antisense oligonucleotide for the treatment of hypercholesterolemia.
ISIS-301012 is an antisense oligonucleotide inhibitor of apolipoprotein B-100, which is being developed by Isis Pharmaceuticals Inc for the potential treatment of hypercholesterolemia. A subcutaneous injectable formulation is currently undergoing phase 11 clinical trials, while phase I trials are underway with an oral formulation of the drug.
Burnett
John R
JR
Royal Perth Hospital, Department of Core Clinical Pathology and Biochemistry, PathWest Laboratory Medicine WA, Wellington Street, GPO Box X2213, Perth, WA 6847, Australia. john.burnett@health.wa.gov.au
D053299:Apolipoprotein B-100 / Q000235:genetics*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy*; D016376:Oligonucleotides, Antisense / Q000009:adverse effects / Q000627:therapeutic use*
D053299:Apolipoprotein B-100; D016376:Oligonucleotides, Antisense